



• INVENTION
• HEALTH
• INSPIRATION

• RESEARCH
• INNOVATION
• TECHNOLOGY

• INVENTORS
• CREATIVITY
• DISCOVERY

• MEDICAL CARE
• SOLUTION
• IDEA

• INVENTORS
• CREATIVITY
• DISCOVERY

2026 INTERIM RESULTS

Human Health Holdings Limited
盈健醫療集團有限公司
01419.HK

Disclaimer

- These materials have been prepared by Human Health Holdings Limited (the “Company”) solely for information use during the Presentation and may not be taken away, copied, reproduced, transmitted, redistributed or passed on, directly or indirectly, to any other person (whether within or outside your company, institution, firm or organization) or published, in whole or in part, for any purpose. “Presentation” means this document, any oral presentations, any question-and-answer sessions and any written material discussed or distributed during the meeting. By attending this Presentation, you are agreeing to be bound by the restrictions set out herein and to maintain absolute confidentiality regarding the information disclosed in these materials. Any failure to comply with these restrictions may constitute a violation of applicable securities laws.
- The information contained in these materials has not been independently verified. No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness, correctness or reasonableness of the information or opinions contained herein. It is not the intention to provide, and you may not rely on these materials as providing, a complete or comprehensive analysis of the Company’s business, financial condition, results of operations, trading position or prospects. Some of the information is still in draft form and will only be finalized at an appropriate time. The information contained in these materials should be considered in the context of the circumstances prevailing at the time and has not been, and will not be, updated to reflect material developments which may occur after the date of the Presentation. None of the Company, nor any of their respective affiliates, directors, supervisors, officers, employees, advisers, agents or representatives, shall have any liability whatsoever (under contract or in tort, for negligence or misrepresentation, or otherwise) for any loss or damage howsoever arising from any use of these materials or their contents or otherwise arising in connection with these materials.
- Certain statements in this Presentation are forward-looking statements that are, by their nature, subject to significant risks and uncertainties and we hereby caution recipients of this Presentation that the Company’s actual performance or results may differ materially from those projected in any forward-looking statements included in this Presentation. Any statements that express, or involve discussions as to expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases, including without limitation, “will,” “expect,” “anticipate,” “estimate,” “believe,” “going forward,” “ought to,” “may,” “seek,” “should,” “would,” “shall,” “intend,” “plan,” “projection,” “could,” “vision,” “goals,” “objective,” “target,” “schedules” and “outlook”) are not historical facts, are forward-looking and may involve estimates and assumptions and are subject to risks, uncertainties and other factors some of which are difficult to predict. Accordingly, these factors could cause actual results or outcomes to differ materially from those expressed in the forward-looking statements. The forward-looking statements herein have been based on assumptions and factors concerning future events that may prove to be in incorrect, inaccurate or incomplete. Those assumptions and factors are based on information currently available to management about the Company’s businesses and industry. No assurance can be given that these expectations will prove to be correct, accurate or complete. The Company does not assume any obligation to update or otherwise revise these forward-looking statements for new information, events or circumstances that occur subsequent to such dates or otherwise.
- Region or elsewhere in the world will contain detailed information about the Company and its management as well as the financial statements of the Company. Any decision to purchase securities in an offering of securities should be made solely on the basis of the information contained in the prospectus or offering circular to be published. By attending this presentation, you acknowledge that you will be solely responsible for your own assessment of the business, financial condition, results of operations, trading and market position or prospects of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the business of the Company.
- Neither this Presentation nor the contents hereof constitutes, in whole or in part, an offer to sell or issue or an offer or invitation to purchase or subscribe for any securities of the Company or its holding company or any of its subsidiaries in any jurisdiction, and no part of it or them may form the basis of or be relied upon in connection with any contract, commitment or investment decision in relation thereto. This Presentation does not constitute
- No securities of the Company may be sold in the United States without registration with the United States Securities and Exchange Commission except pursuant to an exemption from, or in a transaction not subject to, such registration. The Company has not registered and does not intend to register or apply for the registration of any part of the offering in the United States or conduct a public offering in the United States. In Hong Kong, this Presentation must not be sent to anyone other than to “professional investors” as defined in the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and any rules made under that Ordinance. You acknowledge and represent to the Company and their advisers that you are a professional investor, have the knowledge, experience and capability to conduct your own assessment of the Company and its shares and that you have and will conduct your own investigation with respect to the Company and its shares and have obtained or will obtain your own independent advice relating to the investment in the shares of the Company.
- In addition, no shares of the Company may be offered to the public in Hong Kong unless a prospectus in connection with the offering for sale or subscription of such shares has been authorized by The Stock Exchange of Hong Kong Limited for registration with the Registrar of Companies of Hong Kong, failing which a prospectus must not be distributed, issued or circulated in Hong Kong. Any decision to purchase shares of the Company in the offering or sale in Hong Kong or anywhere else should be made solely on the basis of the information contained in the prospectus of the Company. Your access to the information contained herein constitutes an acknowledgment by you that the information contained herein is not (a) an offering of securities of the Company to you or the public for purchase for cash or other consideration; or (b) circulated to invite offers by you or the public to purchase for cash or other consideration any securities of the Company.
- The information contained in this document may be of a price-sensitive nature and the provision of any such information shall constitute you and /or your representatives as “insiders” subject to the laws of the Hong Kong Special Administrative Region or elsewhere. Accordingly, you may not deal in, and will inform your representatives of the restriction against dealing in, any shares in the Company in breach of any applicable laws. You agree to maintain absolute confidentiality regarding the information disclosed in this document. You will be deemed to acknowledge receipt of material non-public information about the Company and its subsidiaries and you will be deemed to represent and agree (i) to maintain absolute confidentiality regarding the information contained in these materials; (ii) to be bound by the restrictions as set forth in this Presentation and to maintain absolute confidentiality regarding any information disclosed (whether written or verbal); (iii) that any use of this information by you other than in accordance with applicable law and stock exchange rules may constitute a violation of the laws or regulations, including in relation to insider dealing/trading; and (iv) that you are solely responsible for any consequences arising from any such violation.

Elevate Your Health Value • Elevate your Life



Business Overview

01 Results Highlights

02 Steady Performance and Network
Refinement in General Practice Segment

03 Consistent Growth of Specialties and
Continued Development of Eye Care Services

04 Step Change for Dental Services

05 Integrated Services at Healthy Square H2

06 Optimised Digital Enablement and
Operational Integration



Results Highlights

Revenue

\$

HK \$ 342.4 million

8.4%

Gross Profit



HK \$ 159.5 million

7.2%

Profit

Attributable
to Owners



HK \$ 18.3 million

8.5%

**Earnings
per Share**



HK 4.8 cents

8.3%





Steady Performance and Network Refinement in General Practice Segment



Cornerstone of diversified healthcare platform

- Revenue increased by 3.5 %

Enhancing the scalability and accessibility of telemedicine service

- Cater to the shifting lifestyle needs of the community



Diversify service mix and proactive community health stance

- Preventive health initiatives and outreach efforts
- Integration of digital health solutions and bespoke concierge care

Maintained close collaboration with the Hong Kong Government

- Active participation in key public health initiatives
- Engage primary healthcare development





Consistent Growth of Specialties and Continued Development of Eye Care Services



- Consistent operational results
- Balanced performance from established services despite a cautious consumer environment
- Persistent demand for specialised care

- Enhance the scope of ophthalmology services to build a comprehensive eye care platform
- Seamless integration between general practice and specialties segments via the integrated clinic operating system and the medical concierge services






Step Change for Dental Services



祐德牙醫診所
Monarch Dental Clinic

健滙牙科
POLY DENTAL

- Revenue increased by 67.5% YoY
- Expanded dental network and strengthened service capacity through acquisition of Monarch Dental



- The existing dental segment achieved stable growth despite intensified market competition
- Focused on operational alignment, practitioner engagement, and system integration to lay the foundation for long-term synergies
- Monarch Dental's established local presence, seasoned practitioner base and brand recognition complement the existing operations





Integrated Services at Healthy Square H2



Specialties
Medical Centre



*A Holistic Healthcare
Destination*

Health
Management
Centre



Healthcare Products
and Services Retail Centre



Day Procedure
Centre



Community
Pharmacy



Multi-functional
Area





Optimised Digital Enablement and Operational Integration




Queuing System

- Dedicated priority queue for elderly patients
- Smoother patient flow
- More predictable service turnaround

eHealth Integration

- Accredited to deposit electronic health records into eHealth
- Built up lifelong and comprehensive health records for individual healthcare.



Omnichannel Messaging Platform

- Appointment booking
- Enquiry management
- Ongoing patient communication

Integrated Clinic Operating System

- Standardised clinical documentation
- Coordinated workflows
- Improved data interoperability across service points



Financial Overview

01 Financial Highlights

02 Revenue Breakdown & Gross
Profit Analysis

03 Financial Position

Financial Highlights

Six months ended 31 December 2025

FY2026

FY2025

Increase / (Decrease)

Operating Results

(HK\$ '000)

(HK\$ '000)

(HK\$ '000)

Revenue

342,351

315,788

26,563

8.4%

Profit attributable to the owners of the company

18,252

16,822

1,430

8.5%

Key Ratios

Net Profit Margin


5.5%

5.3%

--

Revenue Breakdown & Gross Profit Analysis


Six months ended 31 December 2025



FY2025 FY2026

- General practice services
- Specialties services
- Dental services


Revenue: HKD 342.4 Million



FY2025 FY2026

- General practice services
- Specialties services
- Dental services

Gross Profit: HKD 159.5 Million



FY2025 FY2026

- Group's GP margin
- General practice services
- Specialties services
- Dental services

Gross Profit Margin: 46.6%

Financial Position



30.06.2025
(HK\$ '000)

31.12.2025
(HK\$ '000)

Total Assets

1,071,971

1,053,253

**Cash and Cash Equivalents &
Pledged Deposits**

440,931

475,560

Total Liabilities

290,222

266,994

**Interest-Bearing Bank
Borrowings**

16,825

16,092

Gearing Ratio

2.1%

2.0%

Total Equity

781,749

786,259





Business Outlook

- 01 Elevating Service Offerings and Preventive Health**
- 02 Advancing the Digital Healthcare Ecosystem and Remote Consultation**
- 03 Deepening Public-Private Partnerships and Community Impact**
- 04 Strengthening Brand Engagement and Customer Loyalty**



Elevating Service Offerings and Preventive Health



Network expansion

- Demand-driven expansion to increase the accessibility of primary care services
- Maintaining high standards of clinical excellence

Service Diversification


- Specialties: Engaging further professionals and expanding the scope of services
- Dental: Focusing on the expansion of high-end restorative and cosmetic dental services



Advanced Screening and Diagnostic Services

- Transition from a traditional reactive care model to a proactive, “screening-to-management” approach
- Intensify focus on:
 - Liver Health Screening
 - Weight reduction assessment
 - Early-stage Alzheimer’s disease assessment

Advancing the Digital Healthcare Ecosystem and Remote Consultation



- ✓ Advance the Group's digital transformation roadmap to drive operational efficiency and customer engagement
- ✓ Expand telemedicine and telehealth offerings
- ✓ Create a seamless, person-centric digital health journey that encourages long-term customer retention



Deepening Public-Private Partnerships and Community Impact



A Vital partner in Hong Kong's public health infrastructure

- Ongoing participation in the Government's health programmes
- Engaging public authorities and other organisations on primary healthcare development



Promote eHealth

- Contributing to the development of comprehensive electronic health records
- Enabling more accurate and timely diagnoses



Brand Engagement and Customer Loyalty



Developing Brand and Customer Relationship Platforms

- Omnichannel messaging platform
- Medical concierge services
- E-shop membership programme
- H2 Rewards App.



Driving Customers Loyalty touch-points

- Reinforcing brand visibility
- Encouraging repeat engagement
- Positioning our healthcare and wellness ecosystem as a trusted partner for long-term health management





Thank You

Human Health Holdings Limited
盈健醫療集團有限公司
01419.HK